www.fdanews.com/articles/145749-janssen-creates-division-to-launch-tmc435-and-help-conquer-hep-c-in-emea

Janssen Creates Division to Launch TMC435 and Help Conquer Hep C in EMEA

April 19, 2012

Today sees the launch of Janssen Therapeutics EMEA, a division of Janssen Pharmaceuticals, dedicated to bringing the investigational protease inhibitor TMC435 to hepatitis C patients in the EMEA region.
Yahoo! Finance